Acalabrutinib (Calquence) for chronic lymphocytic leukemia - Details


( Last Updated : March 12, 2021)
Generic Name:
Acalabrutinib
Project Status:
Complete
Therapeutic Area:
Chronic Lymphocytic Leukemia (CLL)
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Calquence
Project Line:
Reimbursement Review
Project Number:
PC0211-000
NOC Date:

Details


Strength:
100 mg
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia (CLL)
Funding Request:
As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Review Status:
Complete
Sponsor:
AstraZeneca Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Key Milestones2

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.